Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

Kirschbrown, WP, Kagedal, M, Wang, B et al. (15 more authors) (2019) Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. Cancer Chemotherapy and Pharmacology, 83 (6). pp. 1147-1158. ISSN 0344-5704

Abstract

Metadata

Authors/Creators:
  • Kirschbrown, WP
  • Kagedal, M
  • Wang, B
  • Lindbom, L
  • Knott, A
  • Mack, R
  • Monemi, S
  • Nijem, I
  • Girish, S
  • Freeman, C
  • Fumagalli, D
  • McConnell, R
  • Jerusalem, G
  • Twelves, C
  • Baselga, J
  • von Minckwitz, G
  • Bines, J
  • Garg, A
Copyright, Publisher and Additional Information: (c) 2019, The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Keywords: Pharmacokinetics; Exposure-response; Drug-drug interactions; Pertuzumab
Dates:
  • Published: June 2019
  • Accepted: 25 March 2019
  • Published (online): 11 April 2019
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cancer and Pathology (LICAP) > Clinical Cancer Research (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 15 Jul 2019 15:42
Last Modified: 15 Jul 2019 15:42
Status: Published
Publisher: Springer
Identification Number: https://doi.org/10.1007/s00280-019-03826-1
Related URLs:

Share / Export

Statistics